RBQM's full value exceeds current financial models, with omitted factors like rework reduction and inspection readiness ...
Entrada Therapeutics reports Phase 1/2 data for ENTR-601-45 in exon 45 skipping, the most common single-exon target affecting ...
Vanda Pharmaceuticals' VQW-765 fails primary endpoint in Phase III social anxiety trial, showing no statistically significant ...
“Study builds [in TrialKit] went from anywhere from two to six weeks to one to three to four days. The work Floyd is doing on ...
Zenas BioPharma releases Phase 3 obexelimab IgG4-related disease data with open-label extension results showing durability ...
Heart failure Phase IV studies use digital tools and remote monitoring to reduce patient dropout when perceived personal ...
WCG's Activation Intelligence saves 20+ hours per study activation. Here's what that number means for site startup budgets ...
FDA grants priority review to BridgeBio's oral infigratinib for pediatric achondroplasia, offering a once-daily pill ...
Proteomic aging clocks are moving into clinical trials, but FDA surrogate endpoint standards and assay reproducibility gaps ...
When scan sets split into separate rows, MCAs lose the parent schedule. Here is what that costs you and how to fix it.
TRIUMPH-2's Phase 3 data on retatrutide in 1,152 T2D patients challenges every assumption sponsors hold about GLP-1 trial ...
ArkBio receives FDA clearance for AK0406, a drug-Fc conjugate designed to prevent influenza in adults during the upcoming U.S ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results